Literature DB >> 26857809

A review of induced pluripotent stem cell, direct conversion by trans-differentiation, direct reprogramming and oligodendrocyte differentiation.

Ankshita Prasad1, Janani Manivannan2, Daniel T B Loong1, Soo M Chua1, Payam M Gharibani3, Angelo H All1,2,3,4,5,6,7.   

Abstract

Rapid progress in the field of stem cell therapy and cellular reprogramming provides convincing evidence of its feasibility in treating a wide range of pathologies through autologous cell replacement therapy. This review article describes in detail on three widely used approaches of somatic cell reprogramming: induced pluripotent stem cells, direct conversion and direct reprogramming, in the context of demyelination in the CNS. The potential limitations of each reprogramming technique are reviewed along with their distinct molecular approach to reprogramming. This is followed by an analysis on the scopes and challenges of its translational applications in deriving oligodendrocyte progenitor cells and oligodendrocytes for cell replacement treatment of demyelinating conditions in the CNS.

Entities:  

Keywords:  direct conversion; direct reprogramming; iPSC reprogramming; oligodendrocytes; transdifferentiation

Mesh:

Year:  2016        PMID: 26857809     DOI: 10.2217/rme.16.5

Source DB:  PubMed          Journal:  Regen Med        ISSN: 1746-0751            Impact factor:   3.806


  10 in total

Review 1.  Using induced pluripotent stem cell neuronal models to study neurodegenerative diseases.

Authors:  Xinwen Zhang; Di Hu; Yutong Shang; Xin Qi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-03-18       Impact factor: 5.187

Review 2.  Reprogramming Enhancers in Somatic Cell Nuclear Transfer, iPSC Technology, and Direct Conversion.

Authors:  Daekee Kwon; Minjun Ji; Seunghee Lee; Kwang Won Seo; Kyung-Sun Kang
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

3.  Improved Proliferative Capacity of NP-Like Cells Derived from Human Mesenchymal Stromal Cells and Neuronal Transdifferentiation by Small Molecules.

Authors:  Alejandro Aguilera-Castrejon; Herminia Pasantes-Morales; Juan José Montesinos; Lorena V Cortés-Medina; Marta E Castro-Manrreza; Héctor Mayani; Gerardo Ramos-Mandujano
Journal:  Neurochem Res       Date:  2016-11-02       Impact factor: 3.996

Review 4.  Geroscience: Addressing the mismatch between its exciting research opportunities, its economic imperative and its current funding crisis.

Authors:  George M Martin
Journal:  Exp Gerontol       Date:  2016-11-19       Impact factor: 4.032

5.  Age-Related Macular Degeneration: From Epigenetics to Therapeutic Implications.

Authors:  Michael H Farkas; Margaret M DeAngelis
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 3.650

Review 6.  An Overview of in vitro Methods to Study Microglia.

Authors:  Raissa Timmerman; Saskia M Burm; Jeffrey J Bajramovic
Journal:  Front Cell Neurosci       Date:  2018-08-06       Impact factor: 5.505

Review 7.  The regulatory pathways leading to stem-like cells underlie prostate cancer progression.

Authors:  Chun-Jung Lin; U-Ging Lo; Jer-Tsong Hsieh
Journal:  Asian J Androl       Date:  2019 May-Jun       Impact factor: 3.285

Review 8.  Microglia: Agents of the CNS Pro-Inflammatory Response.

Authors:  José A Rodríguez-Gómez; Edel Kavanagh; Pinelopi Engskog-Vlachos; Mikael K R Engskog; Antonio J Herrera; Ana M Espinosa-Oliva; Bertrand Joseph; Nabil Hajji; José L Venero; Miguel A Burguillos
Journal:  Cells       Date:  2020-07-17       Impact factor: 6.600

Review 9.  Modeling and Targeting Neuroglial Interactions with Human Pluripotent Stem Cell Models.

Authors:  Julie Bigarreau; Nathalie Rouach; Anselme L Perrier; Franck Mouthon; Mathieu Charvériat
Journal:  Int J Mol Sci       Date:  2022-01-31       Impact factor: 5.923

Review 10.  Structural Variation at a Disease Mutation Hotspot: Strategies to Investigate Gene Regulation and the 3D Genome.

Authors:  Alexandra Boyling; Gonzalo Perez-Siles; Marina L Kennerson
Journal:  Front Genet       Date:  2022-03-25       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.